Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2018 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Ironwood Pharma (IRWD) Surges 12% Following Results/Outlook
February 13, 2019 10:02 AM ESTIronwood Pharma (NASDAQ: IRWD) is gaining 12% in early following better-than-expected Q4 results and guidance.
... MoreIronwood Pharma (IRWD) Tops Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Mid-Point Guidance Above Consensus
February 13, 2019 7:05 AM ESTIronwood Pharma (NASDAQ: IRWD) reported Q4 EPS of ($0.10), $0.05 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $130.69 million versus the consensus estimate of $96.57 million.
The fourth quarter capped off a year of solid LINZESS volume growth and progress with our pipeline of seven differentiated product candidates, said... More
